Review article: vascular effects of PPARs in the context of NASH.

Abstract

BACKGROUND:

Peroxisome proliferator-activated receptors (PPARs) are ligand-activated transcription factors known to regulate glucose and fatty acid metabolism, inflammation, endothelial function and fibrosis. PPAR isoforms have been extensively studied in metabolic diseases, including type 2 diabetes and cardiovascular diseases. Recent data extend the key role of PPARs to liver diseases coursing with vascular dysfunction, including nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH).

AIM:

This review summarises and discusses the pathobiological role of PPARs in cardiovascular diseases with a special focus on their impact and therapeutic potential in NAFLD and NASH.

RESULTS AND CONCLUSIONS:

PPARs may be attractive for the treatment of NASH due to their liver-specific effects but also because of their efficacy in improving cardiovascular outcomes, which may later impact liver disease. Assessment of cardiovascular disease in the context of NASH trials is, therefore, of the utmost importance, both from a safety and efficacy perspective.

• Authors: Sergi Guixé-Muntet, Louise Biquard, Gyongyi Szabo, Jean-François Dufour, Frank Tacke, Sven Francque, Pierre-Emmanuel Rautou, Jordi Gracia-Sancho
• Journal: Alimentary pharmacology & therapeutics (Aliment Pharmacol Ther) Vol. 56 Issue 2 Pg. 209-223 (07 2022) ISSN: 1365-2036 [Electronic] England
• PMID: 35661191 (Publication Type: Journal Article, Review, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't)
• Copyright: © 2022 The Authors. Alimentary Pharmacology & Therapeutics published by John Wiley & Sons Ltd.

Chemical References

• Peroxisome Proliferator-Activated Receptors

Topics

• Cardiovascular Diseases (metabolism)
• Diabetes Mellitus, Type 2 (metabolism)
• Humans
• Liver
• Non-alcoholic Fatty Liver Disease (drug therapy)
• Peroxisome Proliferator-Activated Receptors (metabolism, pharmacology, therapeutic use)